CPC A61K 48/0025 (2013.01) [A61K 38/465 (2013.01); A61K 45/06 (2013.01); C12N 5/0693 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); G01N 33/57492 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01); G01N 2333/70567 (2013.01)] | 15 Claims |
1. A method of treating a subject diagnosed with a peroxisome proliferator-activated receptor gamma (PPARG) activated cancer, comprising:
performing an assay to determine the identity of an amino acid at position 447 of PPARG and position 427 of retinoid X receptor alpha (RXRA), wherein a PPARG reference amino acid at position 447 is threonine (T) and a RXRA reference amino acid at position 427 is serine (S);
detecting the presence of a PPARG amino acid variation relative to the PPARG reference amino acid, wherein the PPARG amino acid variation is methionine (M) and a RXRA amino acid variation relative to the RXRA reference amino acid, wherein the RXRA amino acid variation is phenylalanine (F) or tyrosine (Y); and
administering a therapeutically effective amount of a PPARG signaling modulator to the subject having a PPARG T447M variation and/or a RXRA S427F/Y variation.
|